Using scientifically substantiated ingredients and appropriate documentation can help support structure-function claims, but brands should separately substantiate any claim that an ingredient addresses an effect associated with GLP-1 medication use or rapid or significant weight loss
Advanced R&D for stable formulations
Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T
Interestingly, while GLP-1-expressing NTS neurons also project to the ventral striatum [102] and administration of exendin-4 into this brain region reduces food intake and the motivation to obtain a food reward [100, 102], this treatment does not affect ventral striatal dopamine release [103]